Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Amyotrophic Lateral Sclerosis (als) Clinical Trials

22 recruiting trials for Amyotrophic Lateral Sclerosis (als). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
22
Total Trials
22
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT05395624

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET...

Sponsor: Ashvattha Therapeutics, Inc.Enrolling: 653 locations
RECRUITINGNCT07213440

Identification of Early Markers for ALS

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to...

Sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceEnrolling: 601 location
RECRUITINGPhase 1NCT07118319

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With...

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Enrolling: 121 location
RECRUITINGPhase 1NCT05995782

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly...

Sponsor: 1ST Biotherapeutics, Inc.Enrolling: 641 location
RECRUITINGNCT06819124

Examining Interactions Between PALS and Caregivers

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their...

Sponsor: Penn State UniversityEnrolling: 1521 location
RECRUITINGNCT07127172

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of...

The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves...

Sponsor: Neuralink CorpEnrolling: 72 locations
RECRUITINGNCT03233646

Retinal Imaging in Neurodegenerative Disease

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus...

Sponsor: Duke UniversityEnrolling: 20001 location
RECRUITINGNCT07233148

Healing ALS Registry Observational Study (HAROS)

This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study). Participants will...

Sponsor: Healing Advocates Registry and MinistryEnrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT07017946

Intestinal Microbiome Transplant in ALS

This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool...

Sponsor: Duke UniversityEnrolling: 201 location
RECRUITINGNCT06765499

The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With...

Motor Neuron Disease (MND) is the result of dysfunction of the upper motor neurons in the precentral gyrus of the frontal lobe or the lower motor neurons in the ventral horn of...

Sponsor: First People's Hospital of HangzhouEnrolling: 1001 location
RECRUITINGNCT07268833

Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy

The progress of ALS research and clinical practice is hampered by lack of effective biomarkers to monitor disease onset and progression. In response to this urgent need, we will...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 4004 locations
RECRUITINGNCT06681610

Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study

The goal of this clinical trial is to assess the efficacy of TPS of the motor cortex on biomarkers and clinical endpoints in patients with ALS. The main questions it aims to...

Sponsor: Parc de Salut MarEnrolling: 501 location
RECRUITINGNCT07202494

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience...

The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy...

Sponsor: Assistance Publique Hopitaux De MarseilleEnrolling: 7001 location
RECRUITINGNCT07257302

Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis

The goal of this clinical trial is to learn whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong survival in people with...

Sponsor: National Center of Neurology and Psychiatry, JapanEnrolling: 151 location
RECRUITINGPhase 2NCT04244630

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with...

Sponsor: Dallas VA Medical CenterEnrolling: 601 location
RECRUITINGPhase 1NCT06671236

Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases

An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with...

Sponsor: Novabio TherapeuticsEnrolling: 121 location
RECRUITINGNCT06917924

A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS

Amyotrophic Lateral Sclerosis (ALS) is a severe and incurable neurodegenerative disease of motor neurons with a dramatic socio-economic impact on the national health system. ALS...

Sponsor: A.O.U. Città della Salute e della ScienzaEnrolling: 2004 locations
RECRUITINGEarly Phase 1NCT06891716

[18F]ACI-19626 PET in TDP-43 Proteinopathies

The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 \[involved in rare forms of dementia such as...

Sponsor: AC Immune SAEnrolling: 451 location
RECRUITINGNCT06834269

Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.

The objective of the present study is to assess the efficacy of tSMS in ALS patients. This will be achieved by monitoring: * levels of NF-L and other potential innovative...

Sponsor: Campus Bio-Medico UniversityEnrolling: 601 location
RECRUITINGPhase 1 / Phase 2NCT06351592

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation...

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in...

Sponsor: Regeneron PharmaceuticalsEnrolling: 4216 locations
RECRUITINGPhase 2NCT07161999

Study of COYA 302 for the Treatment of ALS

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults...

Sponsor: Coya TherapeuticsEnrolling: 12020 locations
RECRUITINGNCT07521930

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow...

Sponsor: Johns Hopkins UniversityEnrolling: 51 location

Frequently Asked Questions

There are currently 22 clinical trials for Amyotrophic Lateral Sclerosis (als), with 22 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Amyotrophic Lateral Sclerosis (als), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Amyotrophic Lateral Sclerosis (als), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.